WHO has cleared two vaccines designed for the Bundibugyo strain, Oxford's ChAdOx1 and Moderna's mRNA-1469, to join the Tumaini trial in DR Congo once national regulators approve them.
Claimed by: WHO
Everything reported so far traces back to one source. Unverified. We'll update this page as reporting comes in, then say whether it held up.
See it on the map The whole story
Who's reporting it
- Al Jazeera, 2026-11-04: Drawing on AFP and Anadolu, it reports that WHO expert groups recommended adding the Oxford-Serum Institute and Moderna vaccines to the Congo trial, with WHO expecting results in early 2027. source
- UN News, 2026-11-05: It reports WHO's announcement that the two candidates will enter the Tumaini trial after national approvals, on the advice of WHO's vaccine prioritisation advisory group. source
- pharmaphorum, 2026-11-06: It reports the WHO advisory group's recommendation and notes that testing of both candidates still awaits national regulatory sign-off. source
- World Health Organization, 2026-11-06: WHO's outbreak notice lists the two candidates as additions to the Tumaini platform trial that began enrolling in Bunia on 23 October. source
History
- 2026-11-10: Single source. Every report traces to WHO's own announcement of its expert group's recommendation, and the candidates still need national approval before they can be given in the trial.